The move strengthens Kendle’s position in the clinical development industry, adding therapeutic expertise, diversifying its customer base and expanding its capacity to deliver large global trials.
With the completion of the acquisition, Kendle now has nearly 3,000 associates in operations throughout North America, Europe, Asia/Pacific, Latin America and Africa. The combined organization is the fourth largest provider of phase II-IV clinical development services worldwide.
“Our newly combined organization offers our customers an expanded global platform and broadened therapeutic base for their drug development efforts, and positions Kendle for continued strong growth as we accelerate toward our $500 million mid-term revenue goal,” commented Dr Candace Kendle, chairman and CEO.